Rivaroxaban for the prevention and treatment of venous thromboembolism

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 33-38

  Turpie, Alexander G G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Prevention; Rivaroxaban; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HAZARD RATIO; HEMATOMA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SURGICAL RISK; SURGICAL SITE BLEEDING; SYMPTOM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUND HEMATOMA;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MEDICATION ADHERENCE; MORPHOLINES; PRACTICE GUIDELINES AS TOPIC; PYRAZOLES; PYRIDINES; PYRIDONES; THIOPHENES; THROMBOEMBOLISM;

EID: 84855668478     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00980.x     Document Type: Review

References (33)

1. Mackman N., Becker R.C. DVT: a new era in anticoagulant therapy. Arterioscler. Thromb. Vasc. Biol. (2010) 30 369-371.
2. Heit J.A., Cohen A.T., Anderson F.A. Jr., on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) (2005) 106 910.
3. Cohen A.T., Kakkar A.K. Venous thromboembolic disease in cancer patients in Europe - an opportunity for improved prevention: the VITAE thrombosis study. Eur. J. Cancer Suppl. (2005) 3 155. Abstract 557.
4. Spyropoulos A., Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J. Manag. Care Pharm. (2007) 13 475-486.
5. Kyrle P.A., Minar E., Bialonczyk C., Hirschl M., Weltermann A., Eichinger S. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. (2004) 350 2558-2563.
6. Dahl O.E. Orthopaedic surgery as a model for drug development in thrombosis. Drugs (2004) 64 17-25.
7. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest (2008) 133 381S-453S.
8. Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. (2008) 358 2765-2775.
9. Kakkar A.K., Brenner B., Dahl O.E. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet (2008) 372 31-39.
10. Lassen M.R., Ageno W., Borris L.C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. (2008) 358 2776-2786.
11. Turpie A.G.G., Lassen M.R., Davidson B.L. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 373 1673-1680.
12. Eriksson B.I., Kakkar A.K., Turpie A.G.G. et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J. Bone Joint Surg. Br. (2009) 91 636-644.
13. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 370 949-956.
14. Eriksson B.I., Dahl O.E., Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. (2007) 5 2178-2185.
15. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty (2009) 24 1-9.
16. Lassen M.R., Raskob G.E., Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 375 807-815.
17. Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. (2010) 363 2487-2498.
18. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. (2009) 361 594-604.
19. Kearon C., Kahn S.R., Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest (2008) 133 454S-545S.
20. Agnelli G., Gallus A., Goldhaber S.Z. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation (2007) 116 180-187.
21. Buller H.R., Lensing A.W., Prins M.H. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-ranging study. Blood (2008) 112 2242-2247.
22. EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. (2010) 363 2499-2510.
23. ClinicalTrials.gov. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation. [accessed 2011 March 24].
24. ClinicalTrials.gov. MAGELLAN - multicenter, randomized, parallel group efficacy superiority study in hospitalized medically iLL patients comparing rivaroxaban with enoxaparin. [accessed 2011 March 24].
25. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. (2009) 361 2342-2352.
26. ClinicalTrials.gov. Secondary prevention of venous thrombo embolism. [accessed 2011 March 24].
27. ClinicalTrials.gov. Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long term prevention of recurrent symptomatic VTE. [accessed 2011 March 24].
28. ClinicalTrials.gov. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. [accessed 2011 March 24].
29. ClinicalTrials.gov. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. [accessed 2011 March 24].
30. Greaves M. Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion? PLoS Med. (2005) 2 e342.
31. Dantas G.C., Thompson B.V., Manson J.A., Tracy C.S., Upshur R.E. Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam. Pract. (2004) 5 15-23.
32. Caprini J.A., Tapson V.F., Hyers T.M. et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J. Vasc. Surg. (2005) 42 726-733.
33. Gross P.L., Weitz J.I. New anticoagulants for treatment of venous thromboembolism. Arterioscler. Thromb. Vasc. Biol. (2008) 28 380-386.